These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24579307)

  • 1. [The function and application of the IL28B gene in HCV infection and treatment].
    Ma K; Zhang AM; Xia XS
    Yi Chuan; 2013 Nov; 35(11):1244-52. PubMed ID: 24579307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.
    Bellanti F; Vendemiale G; Altomare E; Serviddio G
    Clin Dev Immunol; 2012; 2012():849373. PubMed ID: 22966241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B and the control of hepatitis C virus infection.
    Balagopal A; Thomas DL; Thio CL
    Gastroenterology; 2010 Dec; 139(6):1865-76. PubMed ID: 20950615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
    Thomas DL; Thio CL; Martin MP; Qi Y; Ge D; O'Huigin C; Kidd J; Kidd K; Khakoo SI; Alexander G; Goedert JJ; Kirk GD; Donfield SM; Rosen HR; Tobler LH; Busch MP; McHutchison JG; Goldstein DB; Carrington M
    Nature; 2009 Oct; 461(7265):798-801. PubMed ID: 19759533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
    Lange CM; Zeuzem S
    J Hepatol; 2011 Sep; 55(3):692-701. PubMed ID: 21440591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment.
    Mizokami M
    J Gastroenterol Hepatol; 2012 Mar; 27(3):425-9. PubMed ID: 22168813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
    Rivero-Juarez A; Camacho A; Caruz A; Neukam K; Gonzalez R; Di Lello FA; Perez-Camacho I; Mesa P; Torre-Cisneros J; Peña J; Pineda JA; Rivero A
    AIDS; 2012 May; 26(8):1009-15. PubMed ID: 22382144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immunity and HCV.
    Heim MH
    J Hepatol; 2013 Mar; 58(3):564-74. PubMed ID: 23063572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.
    Laird ME; Mohsen A; Duffy D; Mamdouh R; LeFouler L; Casrouge A; El-Daly M; Rafik M; Abdel-Hamid M; Soulier A; Pawlotsky JM; Hézode C; Rosa I; Renard P; Mohamed MK; Bonnard P; Izopet J; Mallet V; Pol S; Albert ML; Fontanet A
    J Hepatol; 2014 Oct; 61(4):770-6. PubMed ID: 24905490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
    Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
    Matas M; Picornell A; Cifuentes C; Payeras A; Homar F; González-Candelas F; López-Labrador FX; Moya A; Ramon C; Castro JA
    Int Microbiol; 2014 Mar; 17(1):11-20. PubMed ID: 25296442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication.
    Barbera F; Russelli G; Pipitone L; Pietrosi G; Corsale S; Vizzini G; Gridelli B; Conaldi PG
    New Microbiol; 2015 Apr; 38(2):201-10. PubMed ID: 25938745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population.
    Carapito R; Poustchi H; Kwemou M; Untrau M; Sharifi AH; Merat S; Haj-Sheykholeslami A; Jabbari H; Esmaili S; Michel S; Toussaint J; Le Gentil M; Ansari-Moghaddam A; Radosavljevic M; Etemadi A; Georgel P; Malekzadeh R; Bahram S
    Genes Immun; 2015 Dec; 16(8):514-8. PubMed ID: 26378651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?
    Orlent H; Reynaert H; Bourgeois S; Dideberg V; Adler M; Colle I; De Maeght S; Laleman W; Michielsen P; Moreno C; Mulkay JP; Stärkel P; Delwaide J;
    Acta Gastroenterol Belg; 2011 Jun; 74(2):317-22. PubMed ID: 21861317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.
    Asthana M; Sahu SK; Kumar A; Mohanty S; Chakrabarti S; Das P; Chattopadhya NR; Chatterjee K; Singh SP; Rajasubramaniam S; Choudhuri T
    Curr Drug Metab; 2018; 19(3):215-223. PubMed ID: 29380700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.
    Holmes JA; Desmond PV; Thompson AJ
    Clin Liver Dis; 2011 Aug; 15(3):497-513. PubMed ID: 21867933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.